

Cannabis-induced recurrent myocardial infarction in a 21-year-old man: a case report

Dennis Lawin 💿 , Thorsten Lawrenz, Andi Tego, and Christoph Stellbrink 💿 *

Department of Cardiology and Intensive Care Medicine, Klinikum Bielefeld GmbH, Teutoburger Straße 50, Bielefeld D-33604, Germany

Received 15 August 2019; first decision 29 August 2019; accepted 10 February 2020; online publish-ahead-of-print 17 April 2020

Background	Acute coronary syndrome (ACS) is rarely caused by coronary artery disease in young patients unless cardiovascu- lar risk factors are present. Although non-atherosclerotic causes of ACS are rare, they need to be considered in young patients.	
Case summary	We report on a 21-year-old patient referred to our institution with ACS. Electrocardiogram showed ST-segment elevation and coronary angiography revealed thrombotic occlusion of the left anterior descending artery. Reperfusion was achieved by thrombus aspiration, glycoprotein IIb/IIIa inhibitors (GPI), and drug-eluting stent (DES). The patient had no cardiovascular risk factors but reported cannabis consumption before symptom onset. Although he was put on dual antiplatelet therapy and strictly advised to avoid consumption, he continued to abuse cannabis and suffered three further ACS events within 18 months: the first 8 months later caused by thrombotic occlusion of a diagonal branch treated by GPI and DES, the second after 17 months due to thrombotic reocclusion of the diagonal branch, and the third after 18 months by thrombotic occlusion of the circumflex artery, both events treated by GPI alone (all while still using cannabis). Since then, he stopped cannabis consumption and has been symptom-free for 8 months.	
Discussion	This case highlights that cannabis-induced ACS must be considered as a cause of myocardial infarction in young adults. In contrast to ACS in the elderly population, this unusual ACS cause requires specific treatment. The risk of ACS relapse may substantial if cannabis abuse is continued. This potential hazard needs to be taken into consider- ation when legalization of cannabis is discussed.	
Keywords	Acute coronary syndrome • Cannabis • Cardiovascular disease • Case report • Premature myocardial infarction	

Learning points

- Differential diagnosis of acute coronary syndrome (ACS) in the younger population is challenging due to a high number of underlying diseases.
- Cannabis-induced ACS must be considered as a cause of myocardial infarction in young adults and its prevalence may increase due to its legalization in some regions.
- Delta-9-tetrahydrocannabinol, the psychoactive component of cannabis, increases the expression of glycoprotein IIb/IIIa on human platelets, which effects the prothrombotic impact of cannabis.

^{*} Corresponding author. Tel: +49 521 581 3401, Email: christoph.stellbrink@klinikumbielefeld.de

Handling Editor: Elad Asher

Peer-reviewers: Ying Xuan Gue, Zaid Iskandar, and Martina de Knegt

Compliance Editor: Anastasia Vamvakidou

Supplementary Material Editor: Deepti Ranganathan

[©] The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Introduction

Coronary artery disease (CAD) is one of the most prevalent diseases of the elderly population.¹ Although treatment of patients with CAD and acute coronary syndrome (ACS) is part of clinical routine, ACS in young patients can be challenging due to a wide range of causing differential diagnoses.^{2–7} We report on a 21-year-old man suffering from recurrent myocardial infarction (MI) on persistent cannabis consumption. dilatation of the lesion (*Figure 1C* and *D*, Supplementary material online, *Videos S4* and *S5*). During intervention, we used a FilterWire EZ^{TM} -system (Boston Scientific, Marlborough, MA, USA) to protect the peripheral vessels from thrombotic occlusion (Supplementary material online, *Videos S4* and *S5*, *Figure 1*). The culprit lesion was reopened successfully and TIMI III flow could be established (*Figure 1E*, Supplementary material online, *Video S6*). The culprit lesion was reopened successfully (*Figure 1E*, Supplementary material online, *Video S6*). No periprocedural arrhythmias occurred and the patient recovered quickly. Dual antiplatelet therapy (100 mg aspirin once daily and 90 mg ticagrelor twice daily), a betablocker (47.5 mg

Date	Event	Treatment
September 2017	Presentation with chest pain and ST-segment elevation immediately after cannabis consumption. Thrombotic subtotal occlusion of the left anter- ior descending artery was diagnosed	Thrombus aspiration, infusion of glycoprotein IIb/ IIIa inhibitors (GPI) and drug-eluting stent (DES) implantation
May 2018	Thrombotic occlusion of a diagonal branch despite optimal adaption of the previously implanted stent (still using cannabis)	Infusion of GPI and DES implantation
February 2019	Thrombotic re-occlusion of the diagonal branch after 1 year of event-free GPI alone survival despite optimal adaption of the previously implanted stent (still using cannabis)	
March 2019	Thrombotic occlusion of the ramus circumflexus was found (still using cannabis)	GPI alone

Timeline

Case presentation

In September 2017, a 21-year-old male patient was referred to our emergency room with constant substernal chest tightness, unrelated to breathing, with radiation into the left shoulder, lasting for 2 h before admission. Physical examination was unremarkable; there were no additional heart sounds on auscultation and no pulmonary rales. The heart rate was 67 b.p.m. and blood pressure 130/75 mmHg. Jugular venous pressure was not elevated and no pitting oedema was present. On electrocardiogram (ECG), sinus rhythm with ST-segment elevation in the precordial leads and in leads II, III, and aVF was noted (Figure 1A). Laboratory measurements showed elevation of the cardiac biomarkers troponin (0.239 ng/mL; upper limit of normal <0.1 ng/mL) and creatine kinase (initial 469 U/L, peak 1563 U/L; upper limit of normal <169 U/L). Treatment with aspirin 250 mg intravenously was initiated, a heparin infusion started and a loading dose of 180 mg ticagrelor administered. Subsequent coronary angiography showed thrombotic subtotal occlusion of the left anterior descending artery (LAD) at the take-off of the first diagonal branch (Figure 1B; Supplementary material online, Video S2). No other lesions were observed and the remaining coronary arteries did not show any atherosclerotic alterations (Supplementary material online, Video S1). Because coronary blood flow could not be fully re-established by thrombus aspiration (Supplementary material online, Video S3) and infusion of glycoprotein IIb/IIIa inhibitors (GPI), implantation of a drug-eluting stent (DES; $4.0 \times 18 \,\text{mm}$) was necessary after premetoprolol once daily), and a statin (40 mg atorvastatin once daily) were prescribed. Transthoracic echocardiography revealed hypokinesia of the anterior wall resulting in overall mildly reduced left ventricular ejection fraction but no other abnormalities.

To rule out an embolic source for the thrombotic coronary occlusion in this young patient, we additionally performed transoesophageal echocardiography with echo contrast but could not find any evidence for an intracardiac shunt or any other source of cardiac embolism. Moreover, laboratory testing for thrombophilia did not show any abnormalities and testing for autoimmune diseases was negative. Blood lipid and glucose levels were within the normal range. The patient had a history of frequent cannabis abuse but denied cigarette smoking. He had no family history of CAD and did not regularly take any medication. Urine toxicology revealed elevated levels of delta-9tetrahydrocannabinol but was negative for any other drugs. Thus, we considered cannabis abuse as the most likely cause of the MI and strictly advised the patient to avoid further cannabis consumption. The patient was discharged from the hospital in good clinical status under optimal medical treatment. However, the patient continued his cannabis abuse and suffered from three ACS relapses within 2 years, although medication was continued. The first MI occurred 8 months later and was caused by thrombotic occlusion of a diagonal branch despite optimal adaptation of the previously implanted stent in the LAD which was visualized by optical coherence tomography (Figure 2A–C). This occlusion was treated by GPI and implantation of another DES into the diagonal branch (Figure 2D-F). The second relapse was a non-ST elevation ACS in February 2019 and was due to




Figure I (A) Twelve-channel electrocardiogram showing distinct ST-segment elevation in the precordial leads and in II, III, and aVF. (B–E) Coronary angiography (left anterior oblique caudal projection) indicating subtotal stenosis of the left anterior descending artery (white arrow in B). Using a FilterWire EZTM-system (Boston Scientific, Marlborough, MA, USA) to protect the peripheral vessels (white arrowhead in C) dilatation and drug-eluting stent implantation (black arrow in C and D) were performed to recover blood flow (E). A guide wire was placed in the first diagonal branch for sidebranch protection. The left circumflex artery and the right coronary artery (not shown) were normal in angiographic appearance.

thrombotic re-occlusion of the diagonal branch, again despite optimal stent adaptation. One month later, the patient again presented with angina at rest, this time without cardiac enzyme release, caused by thrombotic occlusion of the proximal circumflex artery. Both events were treated by GPI alone. Coronary angiography did not reveal any evidence of coronary dissection in any of the ACS relapses. Cannabis consumption was continued during the whole period. After the fourth ACS, left ventricular ejection fraction was still only mildly reduced. Since the last relapse, the patient stopped cannabis abuse and has been symptom-free for 8 months, i.e. until the last follow-up in November 2019.

Discussion

This case highlights an unusual cause for the overall rare occurrence of an ACS in young patients. In the fourth universal definition of MI consensus document by the European Society of Cardiology, MI was defined as myocardial injury with elevation of cardiac biomarkers and evidence of myocardial ischaemia indicated by ECG changes, specific symptoms or evidence of myocardial damage in imaging.¹ Myocardial infarction can be caused by either plaque rupture/erosion (Type 1), usually affecting patients with underlying CAD, or by an imbalance between oxygen supply and demand (Type 2), which often includes young patients with other aetiologies of MI¹. In contrast to ACS in the elderly population, MI is rarely caused by plaque rupture with underlying CAD in young patients unless a certain number of cardiovascular risk factors are already present.² Differential diagnosis of ACS in the younger population is challenging due to a high number of potential and rare aetiologies. There is limited evidence how to effectively assess the cause of MI in younger patients and knowledge is based on a few case series only.^{2–8} *Table 1* summarizes diseases that have been implicated as causative factors for an ACS in young patients. Thus, in a young patient presenting with ACS a thorough investigation for potential causes of MI is mandatory to enable adequate treatment of the underlying disease and improve prognosis. Careful patient history and physical examination often help to limit differential diagnoses and reach the correct diagnosis.

Our report underlines that cannabis-induced MI should be considered as a rare cause of ACS in young adults. This is emphasized by the fact that the patient was free of events since he stopped cannabis consumption, although there is still a chance that the patient may develop similar symptoms without association to recent cannabis abuse in the future.

Three mechanisms of cannabis-associated ACS have been reported in the literature: coronary vasospasm, thrombus formation, and coronary artery dissection.^{10–12} In the case presented coronary angiography revealed coronary thrombosis without any evidence for




Figure 2 Imaging of the thrombotic occlusion of the first diagonal branch (black arrow in A) 8 months after the first event. (B) Thrombus visualization (white arrow) with optical coherence tomography in the diagonal branch. (C) The previously implanted stent in the left anterior descending artery was well-adapted (white arrowheads). After balloon dilatation (D) implantation of a drug-eluting stent in the diagonal branch was performed using the 'kissing-balloon' technique (E). Coronary blood flow could be fully re-established (F).

Table I Underlying diseases and findings in patient history and physical examination for differential diagnoses of premature myocardial infarction

Underlying disease	Findings in patient history and physical examination
Anomalous coronary artery ⁹	Prior syncope
Autoimmune and vasculitis ⁸	Skin abnormalities, involvement of other organs
Vasospasm ¹⁰	Often female, anamnesis of smoking, drugs
Cardiomyopathies (e.g. takotsubo ¹¹)	Positive/negative stress
Coronary endothelial dysfunction ²	Presence of several cardiovascular risk factors
Embolism ¹²	Atrial fibrillation, patent foramen ovale
Intoxications (e.g. amphetamines, cannabis, cocaine) ³	Anamnesis, conspicuous mental state
Myocarditis ¹³	Fever, myalgia
Sickle cell disease ¹⁴	Country of origin
Spontaneous aortic or coronary artery dissection ¹⁵	History of Marfan syndrome or Syphilis, malperfusion of organs or limbs, pregnancy
Thrombophilia ¹⁶	Family history

vasospasm or dissection. Therefore, calcium channel blockers or nitrates were not used in this specific circumstance. A prothrombotic effect of delta-9-tetrahydrocannabinol, the psychoactive component of cannabis, caused by an increase in the expression of glycoprotein Ilb/Illa on human platelets has been discussed as the underlying mechanism resulting in thrombotic occlusion of non-atherosclerotic coronary arteries.⁵ Infusion of GPI may be beneficial in this setting but is often not sufficient as in the case presented. There is no clear recommendation for the optimal drug regimen after the acute intervention. We decided to prescribe dual antiplatelet therapy for

discharge medication, which is recommended in the current guidelines after percutaneous coronary intervention in ACS.² In the ATLAS ACS 2–TIMI 51 trial, low-dose rivaroxaban has shown beneficial effects in patients with ACS.⁶ A non-vitamin K-dependent oral anticoagulant was not administered in our patient. It may be speculated that low-dose rivaroxaban may have been particularly useful in the setting of repeated intracoronary thrombosis induced by cannabis use although there are yet no data to support this regimen in this specific clinical setting.

This case additionally highlights the potential hazards of cannabis especially for patients maintaining consumption despite complications. A previously published case series illustrated the potential problem of cannabis-induced ACS in early adulthood.⁴ Legalization of cannabis may lead to more widespread use of the drug which may potentially increase the incidence of ACS in young patients.⁷

Conclusion

This case report highlights the potential difficulties in the differential diagnosis of ACS in early adulthood. Prevalence of premature MI caused by cannabis consumption in early adulthood is low but may increase with cannabis legalization.

Lead author biography



Dennis Lawin achieved his license to practice medicine at RWH Aachen University, Germany. After internship at the university hospital of Bern (heart surgery), Switzerland, he finished his doctoral thesis at RWH Aachen, University, Germany. At present, he is a junior physician for cardiology and internal medicine at Klinikum Bielefeld, Germany. His scientific interest is in cardiac resynchronization therapy, emer-

gency care, and electrophysiology.

Supplementary material

Supplementary material is available at European Heart Journal - Case Reports online.

Slide sets: A fully edited slide set detailing this case and suitable for local presentation is available online as Supplementary data.

Consent: The author/s confirm that written consent for submission and publication of this case report including image(s) and associated text has been obtained from the patient in line with COPE guidance.

Conflict of interest: none declared.

References

- Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD; ESC Scientific Document Group. Fourth universal definition of myocardial infarction (2018). *Eur Heart J* 2019;40:237–269.
- 2. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimský P; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018;39:119–177.
- Ramphul K, Mejias SG, Joynauth J. Cocaine, amphetamine, and cannabis use increases the risk of acute myocardial infarction in teenagers. Am J Cardiol 2019; 123:354.
- Sharma N, Lee J, Aponte CS, Marmur JD, Lawson WE, Mann NN, Salifu MO, Youssef I, McFarlane SI. Clinical characteristics and angiographic findings of acute myocardial infarction associated with marijuana use: consecutive case series. *Scifed J Cardiol* 2017;2: 1–11.
- Deusch E, Kress HG, Kraft B, Kozek-Langenecker SA. The procoagulatory effects of delta-9-tetrahydrocannabinol in human platelets. *Anesth Analg* 2004;99: 1127–1130, table of contents.
- Mega JL, Braunwald E, Wiviott SD, Bassand J-P, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KAA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FWA, Gibson CM; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9–19.
- Watson TM, Valleriani J, Hyshka E, Rueda S. Cannabis legalization in the provinces and territories: missing opportunities to effectively educate youth? *Can J Public Health* 2019;**110**:472–475.
- Markham R, Rahman A, Tai S, Hamilton-Craig I, Hamilton-Craig C. Myocardial infarction from isolated coronary artery vasculitis in a young patient: a rare case. *Int J Cardiol* 2015;**180**:40–41.
- Khalighi K, Sharma M, Toor A, Toor RS, Costacurta G. Anomalous left main coronary artery arising from the right sinus of valsalva in a young man presenting with recurrent syncope and myocardial infarction. *Case Rep Cardiol* 2018;2018: 9805061.
- Dandapantula HK, Spears JR, Chandu L, Katkuri H, Afonso L. Cigarette smoking and myocardial infarction in young men and women—"Let us not forget coronary vasospasm". Int J Cardiol 2008;**127**:402.
- Elikowski W, Kudliński B, Małek-Elikowska M, Foremska-Iciek J, Baszko A, Skrzywanek P. [Takotsubo cardiomyopathy in a young woman after a traffic accident with blunt chest trauma]. *Pol Merkur Lekarski* 2016;**40**:372–376.
- Voigt P, Bach AG, Surov A. Coronary air embolism in a trauma patient. *Clin Res Cardiol* 2017;**106**:933–934.
- 13. Lee HS, Pai R, Nazzal S, Mukherjee A. STEMI mimicker in a 26-year-old man. BMJ Case Rep 2019;**12**. pii: bcr-2018-224894.
- Pannu R, Zhang J, Andraws R, Armani A, Patel P, Mancusi-Ungaro P. Acute myocardial infarction in sickle cell disease: a systematic review. *Crit Pathw Cardiol* 2008;7:133–138.
- Rawala MS, Naqvi STS, Yasin M, Rizvi SB. Spontaneous coronary artery dissection masquerading as coronary artery stenosis in a young patient. *Am J Case Rep* 2019;20:159–162.
- Walsh JL, Harris BHL, Gharzuddine W, Isma'eel H. Myocardial infarction masquerading as myocarditis in a patient with factor V Leiden: unmasked with MR. BMJ Case Rep 2017; pii: bcr-2017-220652.